To amend the Federal Food, Drug, and Cosmetic Act to require prompt reports of marketing status by holders of approved applications for biological products, and for other purposes.
Biologics Market Transparency Act of 2022
This bill requires biologics manufacturers to notify the Food and Drug Administration in advance of withdrawing a product from sale.
Received in the Senate.
Placed on Senate Legislative Calendar under General Orders. Calendar No. 444.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S2709)
Introduced in House
Introduced in House
Referred to the House Committee on Energy and Commerce.
Referred to the Subcommittee on Health.
checking server…
Ask anything about this bill. The AI reads the full text to answer.
Enter to send · Shift+Enter for new line